BENSALEM, Pa.–Law Offices of Howard G. Smith announces that it is investigating potential claims against Sequenom, Inc. (“Sequenom” or the “Company”) (Nasdaq:SQNM – News), concerning possible securities violations related to public statements made by the Company between June 4, 2008 and April 29, 2009. The investigation focuses on allegations that certain statements made by the Company during that period regarding the clinical data and efficacy of Sequenom’s noninvasive prenatal genetic test for Down Syndrome were false and misleading.

On April 29, 2009, Sequenom disclosed that the Company’s employees had mishandled data that invalidates previous pronouncements about the effectiveness of the prenatal Down Syndrome test. On this news, shares of Sequenom declined $11.29 per share, more than 75%, to close at $3.62 per share on April 30, 2009.

If you purchased Sequenom common stock between June 4, 2008 and April 29, 2009, or if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to Howardsmith@Howardsmithlaw.com.